Thiazolidinediones, a type of PPARγ agonist, are used to treat type 2 diabetes mellitus (T2DM) because its effect of promoting insulin sensitization, suggesting that PPARγ activation is beneficial to ameliorate diabetic cardiomyopathy (54). This evidence concerns the gene INS and type 2 diabetes mellitus.